Undisclosed drug conjugate / CyGenica - LARVOL DELTA

CyGenica Limited Secures USFDA Approval for Orphan Drug Designation for Novel Drug Conjugate in Glioblastoma Multiforme Treatment (PRNewswire) - "CyGenica Limited...announced today a significant achievement in the battle against Glioblastoma Multiforme (GBM), a highly aggressive form of brain cancer. Dr. Nusrat J M Sanghamitra, Co-founder and CEO of CyGenica, revealed that the U.S. Food and Drug Administration (USFDA) has granted Orphan Drug Designation for their revolutionary drug conjugate for the treatment of GBM."

Orphan drug • Glioblastoma